Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Operations

v3.21.2
Condensed Consolidated Statements of Operations - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Income Statement [Abstract]        
Revenue, net $ 9,472 $ 8,248 $ 30,461 $ 22,752
Cost of revenue (excluding amortization of $1,112 and $1,115 for the three months and $3,336 and $3,346 for the nine months, respectively) 5,848 5,194 16,965 15,156
Gross profit 3,624 3,054 13,496 7,596
Operating expenses:        
Sales and marketing 2,456 2,699 7,585 6,776
Research and development 416 763 1,475 2,123
General and administrative 3,278 3,795 9,582 12,683
Transition expenses 363 687 2,474 798
Gain on DiamiR transaction (235)
Acquisition related amortization expense 1,112 1,115 3,336 3,346
Total operating expenses 7,625 9,059 24,217 25,726
Operating loss (4,001) (6,005) (10,721) (18,130)
Interest accretion expense (106) (138) (375) (414)
Related party interest (151) (372)
Other income (expense), net 45 (12) (255) 473
Loss from continuing operations before tax (4,213) (6,155) (11,723) (18,071)
(Benefit) provision for income taxes (714) 14 (684) 43
Loss from continuing operations (3,499) (6,169) (11,039) (18,114)
Loss from discontinued operations, net of tax (62) (65) (175) (194)
Net loss (3,561) (6,234) (11,214) (18,308)
Less adjustment for preferred stock deemed dividend (3,033)
Net loss attributable to common stockholders $ (3,561) $ (6,234) $ (11,214) $ (21,341)
Basic and diluted loss per share of common stock:        
From continuing operations $ (0.84) $ (1.53) $ (2.68) $ (5.25)
From discontinued operations (0.01) (0.01) (0.04) (0.05)
Net loss per basic and diluted share of common stock $ (0.85) $ (1.54) $ (2.72) $ (5.30)
Weighted average number of common shares and common share equivalents outstanding:        
Basic 4,165 4,038 4,119 4,025
Diluted 4,165 4,038 4,119 4,025